| Bioactivity | Olgotrelvir sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells[1]. |
| Name | Olgotrelvir sodium |
| CAS | 2763596-72-9 |
| Formula | C22H29N4NaO7S |
| Molar Mass | 516.54 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19. |
Olgotrelvir sodium
CAS: 2763596-72-9 F: C22H29N4NaO7S W: 516.54
Olgotrelvir sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cath
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.